Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Tóm tắt
Từ khóa
Tài liệu tham khảo
Eshhar, 1993, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors, Proc Natl Acad Sci U S A, 90, 720, 10.1073/pnas.90.2.720
Kochenderfer, 2013, Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors, Nat Rev Clin Oncol, 10, 267, 10.1038/nrclinonc.2013.46
Sadelain, 2013, The basic principles of chimeric antigen receptor design, Cancer Discov, 3, 388, 10.1158/2159-8290.CD-12-0548
Johnson, 2017, Driving gene-engineered T cell immunotherapy of cancer, Cell Res, 27, 38, 10.1038/cr.2016.154
Rouce, 2017, Recent advances in T-cell immunotherapy for haematological malignancies, Br J Haematol, 176, 688, 10.1111/bjh.14470
Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222
Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3
Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309
Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, 5, 177ra38, 10.1126/scitranslmed.3005930
Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226
Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866
Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919
Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415
Turtle, 2017, Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib, J Clin Oncol, 35, 3010, 10.1200/JCO.2017.72.8519
Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849
Fraietta, 2018, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nat Med, 24, 563, 10.1038/s41591-018-0010-1
Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388
Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025
Turtle, 2016, Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 355ra116, 10.1126/scitranslmed.aaf8621
Kochenderfer, 2017, Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels, J Clin Oncol, 35, 1803, 10.1200/JCO.2016.71.3024
Locke, 2017, Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 Anti-CD19 CAR T cell therapy in refractory aggressive lymphoma, Mol Ther, 25, 285, 10.1016/j.ymthe.2016.10.020
Kochenderfer, 2017, Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy, Mol Ther, 25, 2245, 10.1016/j.ymthe.2017.07.004
Brudno, 2018, Chimeric antigen receptor T-cell therapies for lymphoma, Nat Rev Clin Oncol, 15, 31, 10.1038/nrclinonc.2017.128
Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447
Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566
Abramson, 2018, Updated safety and long term clinical outcomes in TRANSCEND NhL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL
Schuster, 2017, Primary Analysis of JULIET, A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Ali, 2016, T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma, Blood, 128, 1688, 10.1182/blood-2016-04-711903
Brudno, 2018, T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma, J Clin Oncol, 36, 2267, 10.1200/JCO.2018.77.8084
Mikkilineni, 2017, Chimeric antigen receptor T-cell therapies for multiple myeloma, Blood, 130, 2594, 10.1182/blood-2017-06-793869
Wang, 2017, Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-Label phase I trial, Clin Cancer Res, 23, 1156, 10.1158/1078-0432.CCR-16-1365
Ramos, 2017, Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes, J Clin Invest, 127, 3462, 10.1172/JCI94306
Brown, 2016, Regression of glioblastoma after chimeric antigen receptor T-cell therapy, N Engl J Med, 375, 2561, 10.1056/NEJMoa1610497
Adusumilli, 2014, Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity, Sci Transl Med, 6, 261ra151, 10.1126/scitranslmed.3010162
Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood, 118, 6050, 10.1182/blood-2011-05-354449
Ahmed, 2015, Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma, J Clin Oncol, 33, 1688, 10.1200/JCO.2014.58.0225
FDA approval brings first gene therapy to the United States: CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. United States Food and Drug Administration Press ReleaseAugust 30, 2017.
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma: Yescarta is the second gene therapy product approved in the U.S. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm. United States Food and Drug Administration Press ReleaseOctober 18, 2017.
FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606540.htm. United States Food and Drug Administration Press ReleaseMay 1, 2018.
Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751
Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729
Neelapu, 2018, Chimeric antigen receptor T-cell therapy - assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148
Frey, 2017, Cytokine release syndrome: who is at risk and how to treat, Best Pract Res Clin Haematol, 30, 336, 10.1016/j.beha.2017.09.002
Brudno, 2016, Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing Graft-Versus-Host disease, J Clin Oncol, 34, 1112, 10.1200/JCO.2015.64.5929
Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040
Fitzgerald, 2017, Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia, Crit Care Med, 45, e124, 10.1097/CCM.0000000000002053
Kochenderfer, 2013, Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation, Blood, 122, 4129, 10.1182/blood-2013-08-519413
Jensen, 2010, Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans, Biol Blood Marrow Transplant, 16, 1245, 10.1016/j.bbmt.2010.03.014
Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931
Wang, 2014, Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells, Clin Immunol, 155, 160, 10.1016/j.clim.2014.10.002
Santomasso, 2018, Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL), Cancer Discov, 8, 958, 10.1158/2159-8290.CD-17-1319
Brooks, 2016, CAR T-Cell Leukemia Trial put on hold after two Deaths, Medscape Medical News
Hill, 2018, Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy, Blood, 131, 121, 10.1182/blood-2017-07-793760
Park, 2018, Cytokine release syndrome grade is a predictive marker for infections in relapsed or refractory B-cell all patients treated with CAR T cells, Clin Infect Dis, 67, 533, 10.1093/cid/ciy152
Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov, 7, 1404, 10.1158/2159-8290.CD-17-0698
Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208
Hay, 2017, Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy, Blood, 130, 2295, 10.1182/blood-2017-06-793141
Gattinoni, 2005, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, J Exp Med, 202, 907, 10.1084/jem.20050732
Klebanoff, 2005, Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy, Trends Immunol, 26, 111, 10.1016/j.it.2004.12.003
North, 1982, Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells, J Exp Med, 155, 1063, 10.1084/jem.155.4.1063
Kochenderfer, 2010, Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells, Blood, 116, 3875, 10.1182/blood-2010-01-265041
Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540
Teachey, 2018, Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL', Nat Rev Clin Oncol, 15, 218, 10.1038/nrclinonc.2018.19
Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients, J Clin Invest, 121, 1822, 10.1172/JCI46110
Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc Natl Acad Sci U S A, 106, 3360, 10.1073/pnas.0813101106
Alabanza, 2017, Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by Hinge and transmembrane domains, Mol Ther, 25, 2452, 10.1016/j.ymthe.2017.07.013
Brudno, 2018, Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions
Fry, 2018, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat Med, 24, 20, 10.1038/nm.4441
Jac, 2017, Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: Updated results from a multicenter study of bb2121 anti-BCMA CAR T-cell therapy
Pennell, 2018, Human CD19-targeted mouse T cells induce B cell aplasia and toxicity in human CD19 Transgenic mice, Mol Ther, 26, 1423, 10.1016/j.ymthe.2018.04.006
Norelli, 2018, Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells, Nat Med, 24, 739, 10.1038/s41591-018-0036-4
Giavridis, 2018, CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade, Nat Med, 24, 731, 10.1038/s41591-018-0041-7
Taraseviciute, 2018, Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates, Cancer Discov, 8, 750, 10.1158/2159-8290.CD-17-1368
Shalabi, 2018, Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy, J Immunother, 41, 350, 10.1097/CJI.0000000000000241
Le, 2018, FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome, Oncologist, 23, 943, 10.1634/theoncologist.2018-0028
Shetty, 2014, Tocilizumab in the treatment of rheumatoid arthritis and beyond, Drug Des Devel Ther, 8, 349
Gardner, 2016, Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management, Blood, 128, 586, 10.1182/blood.V128.22.586.586
Singh, 2017, Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function, Cytotherapy, 19, 867, 10.1016/j.jcyt.2017.04.001
Nellan, 2018, Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques, Blood, 132, 662, 10.1182/blood-2018-05-846428
Paszkiewicz, 2016, Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia, J Clin Invest, 126, 4262, 10.1172/JCI84813
Gargett, 2014, The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells, Front Pharmacol, 5, 235, 10.3389/fphar.2014.00235
Zhou, 2015, Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation, Blood, 125, 4103, 10.1182/blood-2015-02-628354
Jones, 2014, Improving the safety of cell therapy products by suicide gene transfer, Front Pharmacol, 5, 254, 10.3389/fphar.2014.00254
Drent, 2016, Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma, Haematologica, 101, 616, 10.3324/haematol.2015.137620
Hoyos, 2010, Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety, Leukemia, 24, 1160, 10.1038/leu.2010.75
Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360
Minagawa, 2016, In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia, PLoS One, 11, 10.1371/journal.pone.0166891
Maus, 2016, Making better chimeric antigen receptors for adoptive T-cell therapy, Clin Cancer Res, 22, 1875, 10.1158/1078-0432.CCR-15-1433